Venezuela rejects "absurd" rumors over Chavez's death

CARACAS (Reuters) - Senior aides and relatives of Venezuela's Hugo Chavez countered on Friday a crescendo of rumors that the socialist president may be dead from cancer, saying he was still battling for his life.

"There he is, continuing his fight, his battle, and we are sure of victory!" his older brother Adan Chavez, the governor of Barinas state, told cheering supporters.

Speculation about Chavez, 58, hit fever pitch this week, fed in part by assertions from Panama's former ambassador to the Organization of American States (OAS), Guillermo Cochez, that the Venezuelan leader had died.

"The launching of absurd and bizarre rumors by the right wing simply discredits them and isolates them further from the people," said Chavez's son-in-law Jorge Arreaza, adding that the president was "calm" in a hospital with his family and doctors.

Apart from one set of photos showing Chavez lying in a Havana hospital bed, he has not been seen nor heard from in public since December 11 surgery in Cuba, his fourth operation.

The president made a surprise pre-dawn return to a military hospital in Caracas last week, with none of the fanfare that had accompanied his previous homecomings after treatment.

Vice President Nicolas Maduro, the OPEC nation's de facto leader and Chavez's preferred successor, urged Venezuelans to stay calm, patient and respectful of the president's state.

"The treatments Commander Chavez is receiving are tough, but he is stronger than them," Maduro said after a Catholic Mass in Chavez's honor at a chapel in the hospital.

"He's in good spirits, battling ... . Leave him in peace. He deserves respect for his treatments, because he's a man who has given everything for our fatherland."

Opposition politicians accuse the government of being deceitful about Chavez's condition, and compare the secrecy over his medical details with the transparency shown by other Latin American leaders who have suffered cancer.

"Maduro has lied repeatedly to the president's supporters and to Venezuelans about his real situation," opposition leader Henrique Capriles said on Friday. "Let's see how they explain to the nation in coming days all the lies they have told."

Panamanian diplomat Cochez said Chavez's relatives had switched off his life support several days ago after he had been in a vegetative state since the end of December. He challenged officials to prove him wrong by showing the president in public.

HIGH STAKES

Across the South American nation of 29 million people, Venezuelans are extremely anxious, speculating almost non-stop about Chavez's condition and wondering what the potential end of his 14-year rule might mean for them.

Adding to the tension, several dozen opposition-supporting students have chained themselves together in a Caracas street, demanding to see the president and arguing that Maduro has no right to rule because he was not elected.

With the country on edge, the relatively routine shooting by police of a murder suspect during a gun battle in downtown Caracas on Friday forced Information Minister Ernesto Villegas to take to Twitter to issue reassurances.

"(Some people) took advantage of the episode to try to sow panic in the city center," he said. "The situation is calm."

Should Chavez die or step down, a vote would be held within 30 days, probably pitting Maduro against Capriles for leadership of the country which boasts the world's biggest oil reserves.

The stakes are high for the region, too. Chavez has been the most vocal critic of Washington in Latin America and financed hefty aid programs for leftist governments from Cuba to Bolivia.

Amid the flurry of rumors, Spain's ABC newspaper said on Friday that Chavez had been taken to a presidential retreat on La Orchila island in the Caribbean off Venezuela's coast with his closest family to face the "final stages" of his cancer.

Venezuelan officials have frequently lambasted ABC as being part of an "ultra-right" conspiracy spreading lies about Chavez.

"The bourgeoisie harass him and they assault him constantly," added Maduro, singling out ABC and Colombia's Caracol radio for particular criticism.

"Stop the attacks on the commander! Stop the rumors, stop trying to create instability!"

In the latest of a series of short updates on Chavez's health, the government said last week that his breathing difficulties had worsened, and he was using a tracheal tube.

Officials say he suffered a severe respiratory infection following the six-hour operation he had in December for a cancer that was first detected in his pelvic region in June 2011.

Chavez has never said what type of cancer he has.

Remarkably, two opinion polls this week showed that a majority of Venezuelans - 60 percent in one survey, 57 percent in another - believe he will be cured.

Chavez's millions of passionate supporters, who love his down-to-earth style and heavy spending of oil revenue on welfare policies, are struggling to imagine Venezuela without him.

"Of course, he's coming back, back to government," said Jose Urbina, 47, though he was also buying photos of Chavez at a pro-government rally as mementoes. "I want to remember him. I want to put them in my house."

(Additional reporting by Girish Gupta; Editing by Kieran Murray and Xavier Briand)

Read More..

David Bowie Makes Triumphant Comeback with New Album: PEOPLE's Critic

By Chuck Arnold

03/01/2013 at 08:40 PM EST

Ten years after his last album, David Bowie is back – and so is his swagger.

Forget the moody musings of "Where Are We Now?" – the reflective comeback single that he dropped, seemingly out of nowhere, on his birthday last month (Jan. 8). The Next Day – which, though not released until March 12, began streaming in its entirety on iTunes on Friday – represents much more of an emphatic, energetic return from the 66-year-old Rock and Roll Hall of Famer.

"We'll never be rid of these stars/ But I hope they live forever," sings Bowie, sounding like the immortal rock god he is over the glittering guitar-pop bounce of "The Stars (Are Out Tonight)."

It's one of many driving, guitar-charged tracks on The Next Day: You can just imagine Ziggy Stardust getting his groove on to the bouncy beat of "Dancing Out in Space," while "(You Will) Set the World on Fire" is a rocking, fist-pumping anthem for today's young Americans.

Elsewhere, "Dirty Boys" is a sleazy grinder that, with its saxed-up funkiness, harks back to his soulful periods like 1975's Young Americans. In another nod to Bowie's past, The Next Day was produced by Tony Visconti, who also worked on the star's Berlin Trilogy albums from 1977 to 1979.

On one of the standouts, the melodic, midtempo "I'd Rather Be High," the album takes a political turn with Bowie's anti-war message: "I'd rather be dead or out of my head/ Then training these guns on those men in the sand."

It's moments like these that make The Next Day a triumphant comeback from a much-missed icon.

Read More..

With record highs in sight, stocks face roadblocks

NEW YORK (Reuters) - If Wall Street needs to climb a wall of worry, it will have plenty of opportunity next week.

Major U.S. stock indexes will make another attempt at reaching all-time records, but the fitful pace that has dominated trading is likely to continue. Next Friday's unemployment report and the hefty spending cuts that look like they about to take effect will be at the forefront.

The importance of whether equities can reach and sustain those highs is more than Wall Street's usual fixation on numbers with psychological significance. Breaking through to uncharted territory is seen as a test of investors' faith in the rally.

"It's very significant," said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama.

"The thinking is, there's just not enough there for an extended bull run," he said. "If we do break through (record highs), then maybe the charts and price action are telling us there's something better ahead."

Flare-ups in the euro zone's sovereign debt crisis and next Friday's report on the U.S. labor market could jostle the market, though U.S. job indicators have generally been trending in a positive direction.

Small- and mid-cap stocks hit lifetime highs in February. Now the Dow Jones industrial average <.dji> and the S&P 500 <.spx> are racing each other to the top. The Dow, made up of 30 stocks, is about 75 points - less than 1 percent - away from its record close of 14,164.53, which it hit on October 9, 2007. The broader S&P is still 3 percent away from its closing high of 1,565.15, also reached on October 9, 2007.

The advantage may be in the Dow's court. So far in 2013, it has gained 7.5 percent, beating the S&P 500 by about 1 percent.

THE RALLY AND THE REALITY CHECK

The Dow's relative strength owes much to its unique make-up and calculation, as well as to investors' recent preference for buying value stocks likely to generate steady reliable gains, rather than growth stocks.

But the more defensive stance illustrates how stock buyers are getting concerned about this year's rally. While investors don't want to miss out on gains, they're picking up companies that are less likely to decline as much as high-flying names - if a market correction comes.

The Russell Value Index <.rav> is up 7.6 percent for the year so far, outpacing the Russell Growth Index's <.rag> 5.7 percent rise. Within the realm of the S&P 500, the consumer staples sector led the market in February, gaining 3.1 percent.

There is some concern that growth-oriented names are being eclipsed by defensive bets, said Ryan Detrick, senior technical strategist at Schaeffer's Investment Research in Cincinnati.

"This isn't a be-all and end-all sell signal by any means, but we would feel much more comfortable if some of the more aggressive areas, like technology and small caps, would start to gain some leadership here," Detrick said.

Signs that investors are becoming concerned about the rally's pace is evident in the options market, where the ratio of put activity to call activity has recently shifted in favor of puts, which represent expectations for a stock to fall.

"We are seeing some put hedging in the financials, building up for the past month," said Henry Schwartz, president of options analytics firm Trade Alert in New York.

The put-to-call ratio representing an aggregate of about 562 financial stocks is 1:1, when normally, calls should be outnumbering puts.

Investors have no shortage of reasons to crave the relative safety of blue chips and defensive stocks. Although markets have mostly looked past uncertainty over Washington's plans to cut the deficit, fiscal policy negotiations still pose a risk to equities.

The $85 billion in spending cuts set to begin on Friday is expected to slow economic growth this year if policymakers do not reach a new deal. Markets so far have held firm despite the wrangling in Washington, but tangible economic effects could pinch stock prices going forward.

The International Monetary Fund warned that full implementation of the cuts would probably take at least 0.5 percentage point off U.S. growth this year.

EASY MONEY AND TEPID HIRING

Investors will also take in a round of economic data at a time when concerns are percolating that the market is being pushed up less by fundamentals and more by loose monetary policy around the world.

The main economic event will be Friday's non-farm payrolls report for February. The U.S. economy is expected to have added 160,000 jobs last month, only a tad higher than in January, in a sign the labor market is healing at a slow pace. The U.S. unemployment rate is forecast to hold steady at 7.9 percent.

While lackluster data has been a catalyst in the past for stock market gains as investors bet it would ensure continued stimulus from the Federal Reserve, that sentiment may be wearing thin.

Markets stumbled last week following worries that the Fed might wind down its quantitative easing program sooner than expected.

"It shows the underpinning of the market is being driven at this point by monetary policy," Hellwig said.

With investors questioning what is behind the rally, it will make a run to record highs even more significant, Hellwig added.

"There's smart people that are in the bull camp and the bear camp and the muddle-through camp," Hellwig said. "The fact that you can statistically, using historical evidence, make a case for going higher, lower, or staying the same makes this number very important this time around."

(Wall St Week Ahead runs every Friday. Comments or questions on this column can be emailed to: leah.schnurr(at)thomsonreuters.com)

(Reporting by Leah Schnurr; Additional reporting by Doris Frankel in Chicago; Editing by Jan Paschal)

Read More..

Josh Duhamel Prepares for Parenthood with a 'Low-Key' N.Y.C Night

Caught in the Act

UPDATED
03/01/2013 at 06:00 AM EST

• Originally published 03/01/2013 at 06:00 AM EST

Josh Duhamel might be ready to take on daddy duties, but that doesn't mean he's forgotten how to work a red carpet.

The Safe Haven actor stepped out on Tuesday to celebrate his Moves magazine cover at TOY Restaurant in New York City.

After "glowing" while speaking to photographers, Duhamel had a low-key evening, an onlooker tells PEOPLE. "He sat in a corner of the restaurant and enjoyed dinner."

At his table: several sushi rolls, shrimp toast cigars, tuna toro and mahogany chicken.

Duhamel's wife Fergie announced the couple is expecting their first child on Twitter last month.

Read More..

Colin Farrell Celebrates His New Film with Diet Soda

Caught in the Act

02/28/2013 at 06:00 AM EST

Colin Farrell

Paul Bruinooge/Patrick McMullan/Sipa

After the premiere of his new film Dead Man Down on Tuesday, Colin Farrell joined his castmates and friends at Lexington Social House in Hollywood.

Dressed in a Dolce & Gabbana suit, Farrell mingled with the cast and moviegoers for two hours.

"They complimented him on his performance," an onlooker tells PEOPLE. "He was in great spirits."

The actor sipped on diet soda as he kicked back and lounged around the outdoor fire pit.

The movie – a crime drama set in New York City – also stars Terence Howard, Noomi Rapace and Dominic Cooper.

– Jennifer Garcia

Read More..

Medicare paid $5.1B for poor nursing home care

SAN FRANCISCO (AP) — Medicare paid billions in taxpayer dollars to nursing homes nationwide that were not meeting basic requirements to look after their residents, government investigators have found.

The report, released Thursday by the Department of Health and Human Services' inspector general, said Medicare paid about $5.1 billion for patients to stay in skilled nursing facilities that failed to meet federal quality of care rules in 2009, in some cases resulting in dangerous and neglectful conditions.

One out of every three times patients wound up in nursing homes that year, they landed in facilities that failed to follow basic care requirements laid out by the federal agency that administers Medicare, investigators estimated.

By law, nursing homes need to write up care plans specially tailored for each resident, so doctors, nurses, therapists and all other caregivers are on the same page about how to help residents reach the highest possible levels of physical, mental and psychological well-being.

Not only are residents often going without the crucial help they need, but the government could be spending taxpayer money on facilities that could endanger people's health, the report concluded. The findings come as concerns about health care quality and cost are garnering heightened attention as the Obama administration implements the nation's sweeping health care overhaul.

"These findings raise concerns about what Medicare is paying for," the report said.

Investigators estimate that in one out of five stays, patients' health problems weren't addressed in the care plans, falling far short of government directives. For example, one home made no plans to monitor a patient's use of two anti-psychotic drugs and one depression medication, even though the drugs could have serious side effects.

In other cases, residents got therapy they didn't need, which the report said was in the nursing homes' financial interest because they would be reimbursed at a higher rate by Medicare.

In one example, a patient kept getting physical and occupational therapy even though the care plan said all the health goals had been met, the report said.

The Office of Inspector General's report was based on medical records from 190 patient visits to nursing homes in 42 states that lasted at least three weeks, which investigators said gave them a statistically valid sample of Medicare beneficiaries' experiences in skilled nursing facilities.

That sample represents about 1.1 million patient visits to nursing homes nationwide in 2009, the most recent year for which data was available, according to the review.

Overall, the review raises questions about whether the system is allowing homes to get paid for poor quality services that may be harming residents, investigators said, and recommended that the Centers for Medicare & Medicaid Services tie payments to homes' abilities to meet basic care requirements. The report also recommended that the agency strengthen its regulations and ramp up its oversight. The review did not name individual homes, nor did it estimate the number of patients who had been mistreated, but instead looked at the overall number of stays in which problems arose.

In response, the agency agreed that it should consider tying Medicare reimbursements to homes' provision of good care. CMS also said in written comments that it is reviewing its own regulations to improve enforcement at the homes.

"Medicare has made significant changes to the way we pay providers thanks to the health care law, to reward better quality care," Medicare spokesman Brian Cook said in a statement to AP. "We are taking steps to make sure these facilities have the resources to improve the quality of their care, and make sure Medicare is paying for the quality of care that beneficiaries are entitled to."

CMS hires state-level agencies to survey the homes and make sure they are complying with federal law, and can require correction plans, deny payment or end a contract with a home if major deficiencies come to light. The agency also said it would follow up on potential enforcement at the homes featured in the report.

Greg Crist, a Washington-based spokeswoman for the American Health Care Association, which represents the largest share of skilled nursing facilities nationwide, said overall nursing home operators are well regulated and follow federal guidelines but added that he could not fully comment on the report's conclusions without having had the chance to read it.

"Our members begin every treatment with the individual's personal health needs at the forefront. This is a hands-on process, involving doctors and even family members in an effort to enhance the health outcome of the patient," Crist said.

Virginia Fichera, who has relatives in two nursing homes in New York, said she would welcome a greater push for accountability at skilled nursing facilities.

"Once you're in a nursing home, if things don't go right, you're really a prisoner," said Fichera, a retired professor in Sterling, NY. "As a concerned relative, you just want to know the care is good, and if there are problems, why they are happening and when they'll be fixed."

Once residents are ready to go back home or transfer to another facility, federal law also requires that the homes write special plans to make sure patients are safely discharged.

Investigators found the homes didn't always do what was needed to ensure a smooth transition.

In nearly one-third of cases, facilities also did not provide enough information when the patient moved to another setting, the report found.

___

On the Web:

The OIG report: http://1.usa.gov/VaztQm

The Medicare nursing home database: http://www.medicare.gov/NursingHomeCompare/search.aspx?bhcp=1&AspxAutoDetectCookieSupport=1

___

Follow Garance Burke on Twitter at —http://twitter.com/garanceburke.

Read More..

Stock index futures point to slightly higher open

LONDON (Reuters) - Stock index futures pointed to a slightly higher open on Wall Street on Thursday.

Futures for the S&P 500 and the Dow Jones rose 0.2 percent, while contracts on the Nasdaq 100 were up 0.1 percent at 0852 GMT.

European shares also rose as investors took heart from fresh signs that central banks would continue steps to support the world's economy.

Revised U.S. GDP data at 1330 GMT is expected to show the U.S. economy grew by 0.5 percent in the fourth quarter, rather than a 0.1 percent contraction as initially estimated.

Weekly new jobless claims figures, due at the same time, are seen slowing to 360,000 from 362,000 in the previous seven days.

February's Chicago PMI, due out at 1445 GMT, is expected to come in at 54.3, from 55.6 last month.

Liberty Media Corp , which holds a large stake in Barnes & Noble, said on Wednesday it had the power to block a sale of Barnes & Nobles' retail stores and it is waiting to see whether the bookseller's chairman Leonard Riggio will make an offer.

J.C. Penney Co Inc on Wednesday reported its sharpest sales drop since announcing a grand transformation plan 13 months ago, sending shares in the department store operator's shares down 14.5 percent in after hours trading.

Groupon Inc lost a quarter of its market value in after hours trading on Wednesday after the company revealed it began to take a smaller cut of revenue on daily deals during the holidays, sacrificing revenue and profits to attract and keep merchants.

Business software provider Salesforce.com and clothes retailer Gap are due to report results after the market close.

U.S. authorities investigating possible insider trading in ketchup maker H.J. Heinz Co are studying a derivatives bet that was routed through London, the New York Times reported, citing two people briefed on the matter.

Bond insurer MBIA Inc said there was a significant risk that its structured finance insurance unit would be put into liquidation or rehabilitation by its New York regulator if it was unable to settle its claims with Bank of America .

Generic drugmaker Mylan Inc said it will buy a unit of India's Strides Arcolab Ltd for $1.6 billion to expand its presence in the fast-growing injectable drugs market.

The U.S. Justice Department said on Wednesday it has won a $1 billion tax shelter case against Dow Chemical Co that involved a Swiss partnership, Wall Street financial giant Goldman Sachs and international law firm King & Spalding.

The Dow Jones industrial average <.dji> was up 176.32 points, or 1.27 percent, at 14,076.45 on Wednesday. The Standard & Poor's 500 Index <.spx> was up 19.07 points, or 1.27 percent, at 1,516.01. The Nasdaq Composite Index <.ixic> was up 32.61 points, or 1.04 percent, at 3,162.26.

(Reporting by Francesco Canepa; Editing by Alison Williams)

Read More..

Bobby Brown Sentenced to 55 Days in Jail in Drunk Driving Case

02/26/2013 at 09:30 PM EST

Bobby Brown has been sentenced to 55 days in jail and four years probation in his most recent drunk driving arrest.

Brown, 44, was pulled over in Studio City, Calif., on Oct. 24 for driving erratically and was arrested when the officer detected "a strong scent of alcohol." He was charged with DUI and driving on a suspended license.

He was also arrested for driving under the influence in March of 2012.

Brown pled no contest to the charges on Tuesday, reports TMZ. He was also ordered to complete an 18-month alcohol treatment program.

The singer, who married Alicia Etheredge in Hawaii in June of 2012, must report to jail by March 20.

Read More..

Advanced breast cancer edges up in younger women

CHICAGO (AP) — Advanced breast cancer has increased slightly among young women, a 34-year analysis suggests. The disease is still uncommon among women younger than 40, and the small change has experts scratching their heads about possible reasons.

The results are potentially worrisome because young women's tumors tend to be more aggressive than older women's, and they're much less likely to get routine screening for the disease.

Still, that doesn't explain why there'd be an increase in advanced cases and the researchers and other experts say more work is needed to find answers.

It's likely that the increase has more than one cause, said Dr. Rebecca Johnson, the study's lead author and medical director of a teen and young adult cancer program at Seattle Children's Hospital.

"The change might be due to some sort of modifiable risk factor, like a lifestyle change" or exposure to some sort of cancer-linked substance, she said.

Johnson said the results translate to about 250 advanced cases diagnosed in women younger than 40 in the mid-1970s versus more than 800 in 2009. During those years, the number of women nationwide in that age range went from about 22 million to closer to 30 million — an increase that explains part of the study trend "but definitely not all of it," Johnson said.

Other experts said women delaying pregnancy might be a factor, partly because getting pregnant at an older age might cause an already growing tumor to spread more quickly in response to pregnancy hormones.

Obesity and having at least a drink or two daily have both been linked with breast cancer but research is inconclusive on other possible risk factors, including tobacco and chemicals in the environment. Whether any of these explains the slight increase in advanced disease in young women is unknown.

There was no increase in cancer at other stages in young women. There also was no increase in advanced disease among women older than 40.

Overall U.S. breast cancer rates have mostly fallen in more recent years, although there are signs they may have plateaued.

Some 17 years ago, Johnson was diagnosed with early-stage breast cancer at age 27, and that influenced her career choice to focus on the disease in younger women.

"Young women and their doctors need to understand that it can happen in young women," and get checked if symptoms appear, said Johnson, now 44. "People shouldn't just watch and wait."

The authors reviewed a U.S. government database of cancer cases from 1976 to 2009. They found that among women aged 25 to 39, breast cancer that has spread to distant parts of the body — advanced disease — increased from between 1 and 2 cases per 100,000 women to about 3 cases per 100,000 during that time span.

The study was published Tuesday in the Journal of the American Medical Association.

About one in 8 women will develop breast cancer in their lifetime, but only 1 in 173 will develop it by age 40. Risks increase with age and certain gene variations can raise the odds.

Routine screening with mammograms is recommended for older women but not those younger than 40.

Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the results support anecdotal reports but that there's no reason to start screening all younger women since breast cancer is still so uncommon for them.

He said the study "is solid and interesting and certainly does raise questions as to why this is being observed." One of the most likely reasons is probably related to changes in childbearing practices, he said, adding that the trend "is clearly something to be followed."

Dr. Ann Partridge, chair of the federal Centers for Disease Control and Prevention's advisory committee on breast cancer in young women, agreed but said it's also possible that doctors look harder for advanced disease in younger women than in older patients. More research is needed to make sure the phenomenon is real, said Partridge, director of a program for young women with breast cancer at the Harvard-affiliated Dana-Farber Cancer Institute.

The study shouldn't cause alarm, she said. Still, Partridge said young women should be familiar with their breasts and see the doctor if they notice any lumps or other changes.

Software engineer Stephanie Carson discovered a large breast tumor that had already spread to her lungs; that diagnosis in 2003 was a huge shock.

"I was so clueless," she said. "I was just 29 and that was the last thing on my mind."

Carson, who lives near St. Louis, had a mastectomy, chemotherapy, radiation and other treatments and she frequently has to try new drugs to keep the cancer at bay.

Because most breast cancer is diagnosed in early stages, there's a misconception that women are treated, and then get on with their lives, Carson said. She and her husband had to abandon hopes of having children, and she's on medical leave from her job.

"It changed the complete course of my life," she said. "But it's still a good life."

____

Online:

JAMA: http://jama.ama-assn.org

CDC: http://www.cdc.gov/cancer/breast/index.htm

Read More..

Stock index futures signal mixed open

LONDON (Reuters) - Stock index futures pointed to a mixed Wall Street open on Wednesday, with futures for the S&P 500 and Nasdaq 100 indexes slipping 0.1 percent, while futures for the Dow Jones rose 0.1 percent by 0933 GMT.

U.S. durables goods and homes data due out at 1330 and 1500 GMT respectively should provide further clues on the health of the world's largest economy.

The Pentagon program chief for the F-35 warplane slammed its commercial partners Lockheed Martin and Pratt & Whitney on Wednesday, accusing them of trying to "squeeze every nickel" out of the U.S. government and failing to see the long-term benefits of the project.

Pratt & Whitney is 99 percent sure the fan blade problem that grounded the Pentagon's 51 new F-35 fighter jets was not caused by high-cycle fatigue, which could force a costly design change, according to two sources familiar with an investigation by the enginemaker.

Airbus parent EADS predicted higher profit this year on the heels of stronger than expected 2012 earnings and a clampdown on costs, with the development of its A350 jet remaining the biggest wild card in its bid to match rival Boeing .

Partner Communications , Israel's second-largest mobile phone operator, reported weaker-than-expected quarterly profit and said it could have weak earnings throughout 2013 due to fierce competition that has slashed calling rates.

The pan-European FTSEurofirst 300 index <.fteu3> was up 0.1 percent at 1,151.69 points by 1010 GMT on Wednesday while the euro zone's Euro STOXX 50 index <.stoxx50e> also advanced 0.1 percent, although concerns over Italy's political stalemate were likely to cap gains.

The Dow Jones industrial average <.dji> gained 115.96 points, or 0.84 percent, to 13,900.13 at the close on Tuesday. The Standard & Poor's 500 Index <.spx> rose 9.09 points, or 0.61 percent, to 1,496.94. The Nasdaq Composite Index <.ixic> advanced 13.40 points, or 0.43 percent, to close at 3,129.65.

(Reporting by Sudip Kar-Gupta; Editing by Susan Fenton)

Read More..

The Bachelor's Sean Lowe Reveals Final Two

TV Watch

The Bachelor

02/25/2013 at 10:30 PM EST

From left: AshLee, Lindsay and Catherine

Kevin Foley/ABC(3)

And then there were two.

After three incredible dates in Thailand with the remaining women, The Bachelor's Sean Lowe faced a difficult decision at the end of Monday's episode: Would he send home AshLee, Catherine or Lindsay?

Keep reading to find out who got a rose – and who was left heartbroken ...

Sean said goodbye to early favorite AshLee in a surprising elimination that left her virtually speechless.

Visibly upset, AshLee left Sean's side without saying goodbye. She even asked him to not walk her to the waiting car that would take her away.

But Sean did get to explain. "I thought it was you from the very beginning," he said. "This was honestly the hardest decision I've ever had to make ... I think the world of you. I did not want to hurt you."

"This wasn't a silly game for me," AshLee said as the car drove away. "This wasn't about a joy ride. It wasn't about laughing and joking and having fun."

She added: "It's hard to say goodbye to Sean because I let him in ... It's the ultimate [rejection]."

Check back Tuesday morning for Sean Lowe's blog post to read all about his Thailand dates and why he chose to send AshLee home

Read More..

Stock index futures point to small rebound

LONDON (Reuters) - U.S. stock index futures pointed to a slightly higher open on Wall Street on Tuesday, with futures for the S&P 500, the Dow Jones and the Nasdaq 100 up 0.3-0.4 percent at 0916 GMT.

U.S. stocks had suffered their biggest drop since November on Monday after later results pointed to a strong showing in Italian elections by groups opposed to the country's economic reforms. That triggered worry that Europe's debt problems could once again destabilize the global economy.

European markets were playing catchup with that move in early trade on Tuesday, falling sharply as a result.

Standard & Poor's releases its S&P Case/Shiller Home Price Index for December at 1400 GMT, expected to show a rise of 0.5 percent versus a 0.6 percent rise in the previous month.

One hour later, the Conference Board's February consumer confidence was forecast to come in at 61.0 compared with 58.6 in January.

Also at 1500 GMT, new home sales data for January were seen at 381,000 annualized units, compared with 369,000 in December.

Ben Bernanke delivers the first of two days of congressional testimony on the Federal Reserve's semi-annual monetary policy report. Investors will examine Bernanke's words before the Senate Banking Committee closely for any sign he is growing nervous that the potential costs of the U.S. central bank's bond buying might soon outweigh its benefits.

Goldman Sachs Group Inc will begin its annual job cutting process as early as this week, sources familiar with the matter said on Monday, with its equities-trading business bracing for bigger cuts than fixed-income trading.

JPMorgan Chase chief executive Jamie Dimon leads his new team of managers in an annual day of presentations to Wall Street about the outlook for businesses operated by the biggest U.S. bank. The firm named a new head of auto finance on Monday.

Intel Corp has agreed to make chips on behalf of Altera ALTR.O, a significant step toward opening its prized manufacturing technology to customers on a larger scale, potentially including Apple .

Fuelled by a 48 percent rise in fourth-quarter earnings, the top executive of securities firm Stifel Financial Corp's defended his aggressive acquisition spree on Monday.

Retailer Home Depot is expected to post a $0.14 rise in quarterly earnings per share, seen at of $0.64, one day after rival Lowe's reported better-than-expected profit and boosted its outlook for revenue this year.

The Dow Jones industrial average <.dji> dropped 216.40 points, or 1.55 percent, to 13,784.17 on Monday. The Standard & Poor's 500 Index <.spx> lost 27.75 points, or 1.83 percent, to 1,487.85. The Nasdaq Composite Index <.ixic> fell 45.57 points, or 1.44 percent, to 3,116.25.

(Reporting by Francesco Canepa; editing by Patrick Graham)

Read More..

South Korea's new president demands North drop nuclear ambitions

SEOUL (Reuters) - South Korea's new president Park Geun-hye urged North Korea on Monday to abandon its nuclear ambitions, and to stop wasting its scarce resources on arms, less than two weeks after the country carried out its third nuclear test.

In her inauguration speech, the country's first female president, also called on South Koreans to help revive the nation's export-dependent economy whose trade is threatened by neighboring Japan's weak yen policy.

Park, the 61-year-old daughter of South Korea's former military ruler Park Chung-hee, met with the father of North Korea's current ruler in 2002 and offered the impoverished and isolated neighbor aid and trade if it abandoned its nuclear program.

"I urge North Korea to abandon its nuclear ambitions without delay and embark on the path to peace and shared development," Park said after being inaugurated on Monday.

Park, usually an austere and demure figure in her public appearances, wore an olive-drab military style jacket and lavender scarf on Monday and smiled broadly and waved enthusiastically as a 70,000 strong crowd cheered her.

Rap sensation Psy was one of the warm up acts on an early spring day outside the country's parliament and performed his "Gagnam Style" hit, but without some of the raunchier actions.

Park's tough stance was supported by the partisan and largely older crowd at her inauguration.

"I have trust in her as the first female president ... She has to be more aggressive on North Korea," said Jeong Byung-ok, 44, who was at the ceremony with her four-year-old daughter.

PARK FACES CHOICE: PAY OFF PYONGYANG OR ISOLATE NORTH

North Korea is ruled by 30-year-old Kim Jong-un, the third of his line to hold power in Pyongyang and the grandson of a man who tried to assassinate Park's father.

The North, which is facing further U.N. sanctions for its latest nuclear test, which was its biggest and most powerful to date, is unlikely to heed Park's call and there is little Seoul can do to influence its bellicose neighbor.

Park's choices boil down to paying off Pyongyang to abandon its nuclear weapons plan, which would cost hundreds of millions of dollars and failed in 2006 when the North exploded its first nuclear bomb. Alternatively, Seoul could try to further isolate the North, a move that resulted in the 2010 sinking of a South Korean ship and the shelling of a South Korean island.

Referring to the fast economic growth under her father's rule, which drove war-torn South Korea from poverty to the ranks of the world's richest nations, Park urged Koreans to re-create the spirit of the "Miracle on the Han".

Park wants to create new jobs, in a country where young people often complain of a lack of opportunities, and boost welfare, although she hasn't spelled out how she will do either.

Growth in South Korea has fallen sharply since the days of Park's father who oversaw periods of 10 percent plus economic expansion. The Bank of Korea expects the economy to grow just 2.8 percent this year and 2.8 percent in 2014.

Park also faces a challenge from a resurgent Japan whose exports have risen sharply after new Prime Minister Shinzo Abe embarked on a policy to weaken the yen currency.

The won has jumped five percent in 2013 against the yen after a 23 percent gain in 2012, boosting the competitiveness of Japanese exports of cars and electronics against the same goods that South Korean firms produce.

Park last week said she would take "pre-emptive" action on the weak yen, but has yet to specify what action she will take.

(Additional reporting by Jack Kim; Editing by David Chance and Michael Perry)

Read More..

Relive the Best One-Liners and Tweets from the Oscars!

02/25/2013 at 12:00 AM EST

Jennifer Lawrence tumbled – to a standing ovation. Ben Affleck tearfully won Best Picure for Argo. And you all loved – or loved to hate – Oscar host Seth MacFarlane.

Yep, the Oscars are over, but it doesn't mean we're done talking about it! You can relive the best of the night! Check out what celebs, readers (and you!) had to say about the musical numbers, speeches – and a certain reigning Sexiest Man Alive! – on Twitter last night.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Stock index futures point to flat to higher open

LONDON (Reuters) - Stock index futures pointed to a mixed open on Wall Street on Monday, with futures for the S&P 500 and Nasdaq 100 up 0.1 and 0.2 percent respectively by 0856 GMT, while those for Dow Jones were steady.

* The U.S. stock market closed higher on Friday, with the S&P 500 adding 13.18 points, or 0.88 percent, to 1,515.60 <.spx>, after comments from Fed officials allayed fears that the central bank would curtail stimulus measures.

* Prospects of continued stimulus also lifted Asian and European equity markets on Monday, with the EuroSTOXX 50 benchmark of euro zone blue chips up 0.7 percent <.stoxx50e>. However, uncertainty over the outcome of Italian elections, which close on Monday, kept a lid on the gains.

* With days left before $85 billion is slashed from U.S. government budgets, the White House on Sunday issued more dire warnings about the harm the cuts will do to Americans. But Republicans, who advocate budget cuts, said the warning was overplayed and called on President Barack Obama to apply what is known as the "sequester" in a more careful way, rather than slashing budgets across the board.

* A relatively light calendar features the Chicago Fed's national activity index for February at 1330 GMT, alongside earnings from Autodesk Inc and Lowe's Companies.

* Barnes & Noble Inc Chairman Leonard Riggio is considering a bid for the company's bookstore business, the Wall Street Journal reported on Sunday, citing people familiar with the situation.

* Disney's movie "Brave" won the Oscar on Sunday for Best Animated Feature.

* BlackRock Inc. , the world's largest money manager, has got approval from the U.S. securities regulator to list a copper-backed exchange-traded fund, potentially getting the jump on JPMorgan, whose listing of a similar product has been delayed by industry objections.

* Knight Capital Group , which recently agreed to be bought for $1.4 billion by Getco Holding Co, has struck a deal to sell its credit-brokerage unit to Stifel Financial Corp , according to a person familiar with the matter.

* Hewlett-Packard Chairman Ray Lane and fellow board members plan to meet with about 20 of the computer maker's big investors Monday in hopes of heading off a campaign to unseat Lane and two other directors, the Wall Street Journal reports.

* Office Depot Inc said late on Friday that following talks with the largest holder of its common stock, Starboard Value LP, it is extending the deadline for nominating candidates for its board at its annual meeting.

* Dick's Sporting Goods Inc shares could rise 23 percent within the next year if the largest publicly traded U.S. sporting goods retailer continues to boost profit at a mid-teens percentage rate, Barron's said.

(Reporting By Toni Vorobyova; Editing by Hugh Lawson)

Read More..

Italians vote in crucial election for euro zone

ROME (Reuters) - Italians began voting on Sunday in one of the most closely watched elections in years, with markets nervous about whether it can produce a strong government to pull Italy out of recession and help resolve the euro zone debt crisis.

Some of the first people to cast their ballots expressed fears that no clear winner would emerge, leading to political stalemate and a coalition that may not govern for long.

"I think we will have to go to elections again ... I expect instability for the next two years," said Vincenzo D'Ouria, voting in Milan.

Italians started voting at 8 a.m. (0700 GMT). Polling booths will remain open until 10 p.m. on Sunday and open again between 7 a.m. and 3 p.m. on Monday. Exit polls will come out soon after voting ends and official results are expected by early Tuesday.

The election is being followed closely by financial markets with memories still fresh of the potentially catastrophic debt crisis that brought technocrat Prime Minister Mario Monti to power more than a year ago.

Monti and his wife cast their votes at a polling booth in a Milan school on Sunday morning. His centrist bloc would only enter a future government as a junior partner of a bigger party.

Final polls published two weeks ago showed center-left leader Pier Luigi Bersani with a 5-point lead, but analysts disagree about whether he will be able to form a stable majority that can make the economic reforms Italy needs.

Bersani is now thought to be just a few points ahead of center-right rival Silvio Berlusconi, the four-times prime minister who has promised tax refunds and staged a media blitz in an attempt to win back voters.

A huge final rally by anti-establishment-comedian-turned-politician Beppe Grillo on Friday highlighted public anger at traditional parties.

Grillo's 5-Star movement, made up of political novices, is in third place in its first general election, polls suggest, and popular support from voters across the political spectrum has increased uncertainty about the outcome.

"Italians want change, but you cannot achieve that with Grillo. They are far too inexperienced for the Italian parliamentary machine," said Cristina Rossi, 40, a civil engineer who was on her way to vote for Bersani's Democratic Party in Milan.

"I fear the outcome will be a weak government, but maybe this is just a necessary transition to be able, in one or two years, to chose someone who can really govern Italy."

Italy, the euro zone's third-largest economy, is stuck in deep recession, struggling under a public debt burden second only to Greece's in the 17-member currency bloc and with a public weary of more than a year of austerity policies.

BERLUSCONI CRITICISM

Berlusconi hogged the headlines on Sunday after he used news conference at his soccer club AC Milan's training ground to break the campaign silence imposed on politicians in the day before polls open.

He told reporters that Italy's magistrates were "more dangerous than the Sicilian mafia" and had invented allegations he had held sex parties in order to discredit him.

The 76-year-old billionaire, who is appealing a jail sentence for tax fraud and is on trial accused of having sex with an underage prostitute, was criticized by his rivals for making a political statement during a ban on campaigning.

While the center left is still expected to gain control of the lower house, thanks to rules that guarantee a strong majority to whichever party wins the most votes nationally, a much closer battle will be fought for the Senate, which any government also needs to control to be able to pass laws.

Seats in the upper house are awarded on a region-by-region basis, meaning that support in key areas can decisively influence the overall result.

Pollsters still believe the most likely outcome is a center-left government headed by Bersani and possibly backed by Monti.

But strong campaigning by Berlusconi and the fiery Grillo, have thrown the election wide open. Surveys showed up to 5 million voters will make up their minds at the last minute.

The Interior Ministry urged some 47 million eligible voters in Italy not to let bad weather put them off, and said it was prepared to handle snowy conditions in some northern regions to ensure everyone had a chance to vote.

STAGNANT ECONOMY

Whatever government emerges from the vote will have the task of pulling Italy out of its longest recession for 20 years and reviving an economy largely stagnant for two decades.

The main danger for Italy and the euro zone is a weak government incapable of taking firm action, which would rattle investors and could ignite a new debt crisis.

Monti replaced Berlusconi in November 2011 after Italy came close to Greek-style financial meltdown while the center-right government was embroiled in scandals.

The former European Commissioner launched a tough program of spending cuts, tax hikes and pension reforms which won widespread international backing and helped restore Italy's credibility abroad after the scandals of the Berlusconi era.

Italy's borrowing costs have since fallen sharply after the European Central Bank pledged it was prepared to support countries undertaking reforms by buying unlimited quantities of their bonds on the markets.

But economic austerity has fuelled anger among Italians grappling with rising unemployment and shrinking disposable incomes, encouraging many to turn to Grillo, who has tapped into a national mood of disenchantment.

(Additional reporting by Cristiano Corvino and Lisa Jucca in Milan; Editing by Robin Pomeroy)

Read More..

See the Mini Balenciaga Bag Kim Kardashian Gifted Niece Penelope

Mom & Babies
Celebrity Baby Blog

02/22/2013 at 05:00 PM ET

Mom Kourtney Kardashian has one! Aunts Kim and Khloé own one too. And now Penelope Disick is the latest family member to add Balenciaga‘s chic city tote to her closet.

“Penelope is wearing the little Balenciaga bag that I got her for Christmas!” Kim posted on Instagram Friday, along with an adorable photo of the mom-to-be with her 7½-month-old niece and her mini yellow handbag.

Is Kim gearing up for her little one? If she has a little girl, we have no doubt her wardrobe will be the envy of the playground. Although the expectant reality star recently revealed that if it’s up to dad-to-be Kanye West, their baby will be wearing lots of “big chains and leather pants.”

And to be fair, Penelope wasn’t the only Kardashian-Jenner kid to receive luxe fashions for Christmas. Kylie and Kendall also scored during the holidays.

Courtesy Kim Kardashian; Inset: Rex USA

– Shanelle Rein-Olowokere

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.

Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.

Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.

"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.

Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.

But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.

National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.

"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.

OPTIONS BULLS TARGET GAINS

The spending cuts, if they go ahead, could hit the defense industry particularly hard.

Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.

Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.

"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.

The stock ended up 0.6 percent at $88.12 on Friday.

If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.

General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.

EYES ON GDP DATA, APPLE

The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.

U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.

Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.

Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.

On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.

(Additional reporting by Doris Frankel; Editing by Kenneth Barry)

Read More..